<DOC>
	<DOCNO>NCT01957137</DOCNO>
	<brief_summary>The study assess effect different InterStim cycling setting urinary urge incontinence .</brief_summary>
	<brief_title>InterStimÂ® Sacral Nerve Modulation Cycling Study</brief_title>
	<detailed_description>This feasibility study ass follow outcome : - Voiding diary - Patient report assessment response satisfaction - Adverse event</detailed_description>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<criteria>1 . Implanted either Neurostimulator Model 3023 ( InterStim ) Neurostimulator Model 3058 ( InterStim II ) least 3 month 2 . Implanted tined lead model 3889 3093 3 . Tined lead locate S3 determine sensory motor response xray fluoroscopy 4 . Currently show efficacy InterStim device potential optimize per opinion Investigator 5 . Primary diagnosis InterStim implant urinary urge incontinence . 6 . Must willing maintain current regimen ( dosage frequency ) overactive bladder ( OAB ) medication ( anticholinergic , antimuscarinic Myrbetriq ( Mirabegron ) ) tricyclic antidepression medication study duration , applicable . 7 . Female subject 18 year age old 8 . Willing able accurately complete void diary questionnaire , attend visit ( within visit window +7 day ) , comply study protocol include maintenance InterStim programming setting course study 9 . Have one ( InterStim ) reprogramming within 28 day prior randomization 10 . Able consent participate signing Informed Consent Form 11 . History Multiple sclerosis 12 . History Reiter 's syndrome 13 . History spinal cord injury cerebral vascular accident ( CVA ) 14 . History diabetes unless diabetes wellcontrolled diet and/or medication 15 . Active symptomatic urinary tract infection ( UTI ) 16 . Stress incontinence primary diagnosis 17 . Urgency frequency primary diagnosis 18 . Pelvic pain uncertain etiology associate void dysfunction pelvic pain primary diagnosis 19 . Interstitial cystitis primary diagnosis 20 . Urinary retention primary diagnosis 21 . Treatment urinary symptom botulinum toxin past 12 month plan botulinum toxin treatment study 22 . Bilateral lead placement 23 . Have implantable neurostimulator , pacemaker , defibrillator 24 . Have knowledge plan diathermy , microwave exposure , high output ultrasonic exposure , RF energy exposure , MRI scan include within scan condition provide within MRI Guidelines InterStim Therapy neurostimulation system . 25 . Have anticipate system modification within next 5 month 26 . Women pregnant plan become pregnant ( woman childbearing potential must undergo pregnancy test , clear negative result , 7 day prior randomization visit ) 27 . Subjects frequently use patient programmer change device program setting ( `` frequently '' define least day include shut device safety purpose ) 28 . Characteristics indicate poor understanding study characteristic indicate subject may poor compliance study protocol . 29 . Study site personnel contact Medtronic Study Manager ( designee ) determine potential subject plan enroll investigational device drug trial , currently enrol investigational device drug trial eligible study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Urinary</keyword>
	<keyword>Urge</keyword>
	<keyword>Incontinence</keyword>
</DOC>